Analysis of drug coverage before and after the implementation of Canada's Common Drug Review

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 17, 2011, Pages

  Gamble, John Michael ^a   Weir, Daniala L ^a   Johnson, Jeffrey A ^a   Eurich, Dean T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; CANADA; CLINICAL DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG MONITORING; DRUG RESEARCH; HUMAN; SENSITIVITY ANALYSIS; STANDARDIZATION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 81855173449     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110670     Document Type: Article

References (14)

1. Canadian Institute for Health Information. Drug expenditure in Canada 1985 to 2010. Ottawa (ON): The Institute; 2011. p. 1-154.
2. Canadian Agency for Drugs and Technologies in Health. Common Drug Review: procedure for Common Drug Review. Ottawa (ON): The Agency; 2011. Available: cadth .ca /media /cdr /process /CDR-Procedure-e.pdf (accessed 2011 Jan. 14).
3. Tierney M, Manns B. Optimizing the use of prescription drugs in Canada through the Common Drug Review. CMAJ 2008; 178: 432-5. (Pubitemid 351303287)
4. Kallah J. Formulary acceptance: monitoring and evaluation. Provincial Reimbursement Advisor 2006;9:57-77.
5. Wyatt G, Gladu V, McDonald-Taylor K, et al. The 2007 Wyatt Health International Comparison. Access to innovative pharmaceuticals: How do countries compare? Oakville (ON): Wyatt Management Consulting; 2008.
6. Rovere M, Skinner B. Access delayed, access denied: Waiting for new medicines in Canada. 2009 Report. Vancouver (BC): Fraser Institute; 2009. Available: www.fraserinstitute .org /research-news/display.aspx?id=17807 (accessed 2011 Aug. 8)
7. Scobie AC, MacKinnon NJ. Cost shifting and timeliness of drug formulary decisions in Atlantic Canada. Healthc Policy 2010; 5: 100-14.
8. Gamble JM, Eurich DT, Johnson JA. A comparison of drug coverage in Alberta before and after the introduction of the National Common Drug Review process. Healthc Policy 2010;6:e117-44.
9. Grégoire JP, MacNeil P, Skilton K, et al. Inter-provincial variation in government drug formularies. Can J Public Health 2001; 92: 307-12. (Pubitemid 33019488)
10. Anis AH, Guh D, Xh W. A dog's breakfast: prescription drug coverage varies widely across Canada. Med Care 2001; 39: 315-26. (Pubitemid 33603631)
11. Clement FM, Harris A, Li JJ, et al. Using effectiveness and costeffectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009;302:1437-43.
12. Lexchin J, Mintzes B. Medicine reimbursement recommendations in Canada, Australia, and Scotland. Am J Manag Care 2008; 14: 581-8.
13. McMahon M, Morgan S, Mitton C. The Common Drug Review: A NICE start for Canada? Health Policy 2006;77:339-51. (Pubitemid 43946522)
14. Canadian Agency for Drugs and Technologies in Health. Submission Brief to House of Commons Standing Committee on Health April 25, 2007. Ottawa (ON): The Agency; 2007. Available: www .cadth .ca /media/media /CADTH -Submission -to -Standing -Committee -on-Health-070409.pdf (accessed 2011 Aug. 8)